Read all posts
www.cnbc.com

Has Biogen found the ‘Goldilocks’ dose for Alzheimer’s drug?

Biogen is after one key thing: the perfect dose. Highly anticipated data due out next week on its experimental Alzheimer's medicine could show whether aducanumab will be among the first drugs to slow the cognitive declines associated with the disease.

Read the article on CNBC

Dr. Sears Comments:

Dr. Barry Sears

Not surprisingly, the announced data for this drug study was mixed.  That is pharma-talk for saying it didn’t work very well.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

 |